01Dec
Americas Antitrust Review 2021
Covid-19 has made 2020 into a year like no other with ‘stay at home’ orders and working from home the new normal. Nonetheless, the tech and pharma industries continued to attract immense antitrust scrutiny, with daily reports in the media and pressure from politicians to address what some perceive to be anticompetitive mergers by digital platforms and pharmaceutical companies, even while innovation in both sectors continues at breakneck speed. In this article, we discuss some of the most...
By:
Cooley LLP
Related
Corporate M&A activity burned white hot last year, reaching record highs of $1.74 trillion in value ...
Read More >
New York state has enacted sweeping new workplace harassment protections for employees, including lo...
Read More >
It’s 2019 and while the hardship rules are changing for 2020, keep in mind that hardship distributi...
Read More >
In our 2019 End of Year Plan Sponsor “To Do” List (Part 3) Qualified Plans, we suggested that spon...
Read More >
The Sarbanes-Oxley Act (SOX) provides federal whistleblower protections against retaliation for empl...
Read More >
The primary objective of the guidelines is to improve financial reporting by addressing issues relat...
Read More >